These innovative compounds represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://sahilyhji687678.newbigblog.com/45717180/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide